RO5479599

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

NeoplasmsSquamous Non-Small Cell Lung Cancer

Phase 1

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

CompletedNCT01482377

Hoffmann-La RocheNeoplasms

Start: 2011-12-31End: 2016-02-29Updated: 2017-01-27

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

TerminatedNCT02204345

Hoffmann-La RocheSquamous Non-Small Cell Lung Cancer

Start: 2014-10-31End: 2016-03-31Updated: 2017-01-25

Related Papers

EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.

2018-07-2021 citations

<sup>89</sup>Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.

Journal of Clinical Oncology2016-05-201 citations

Phase I imaging study of the HER3 antibody RG7116 using <sup>89</sup>Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.

Journal of Clinical Oncology2014-05-208 citations